新冠疫情期间精神分裂症谱系障碍患者抗精神病药暴露与感染风险:丹麦全国登记研究
该研究利用丹麦多个全国登记库,纳入2020年1月1日至3月1日期间居住于丹麦的85 083例18岁及以上精神分裂症谱系障碍(ICD-10:F20-F29)患者,以时变方式定义抗精神病药暴露,比较暴露期与非暴露期COVID-19及非COVID-19呼吸道感染风险。结果显示,暴露期SARS-CoV-2检测阳性风险降低(HR 0·91),COVID-19相关住院风险升高(HR 1·28),非COVID-19呼吸道感染住院和死亡风险均升高(HR 1·61);氯氮平暴露与其他抗精神病药相比未见明显超额风险。作者认为可对40岁以上开始或正在接受抗精神病药治疗者启动感染防控措施如肺炎球菌疫苗接种,不建议避免使用特定抗精神病药。
要点
- 抗精神病药暴露期较非暴露期SARS-CoV-2检测阳性风险降低(HR 0·91),抗感染药物处方风险无统计学显著差异(HR 1·01)。
- 抗精神病药暴露期COVID-19相关住院风险升高(HR 1·28),COVID-19相关死亡无统计学显著升高(HR 1·24);非COVID-19呼吸道感染住院和死亡风险均升高(HR 1·61)。
- 氯氮平暴露与其他抗精神病药相比未见任何结局的明显超额风险;作者建议对40岁以上开始或正在接受抗精神病药治疗者启动感染防控措施如肺炎球菌疫苗接种。
核心结论
- 抗精神病药暴露期较非暴露期严重感染结局风险升高;作者认为对40岁以上开始或正在接受抗精神病药治疗的精神分裂症谱系障碍患者启动感染防控措施如肺炎球菌疫苗接种似乎是合理的。
- 作者不建议避免使用特定抗精神病药,而是建议遵循治疗指南并呼吁对该高危群体提高警惕。
研究设计与样本
- 使用丹麦多个全国登记库(国家处方登记库、国家医院登记库、精神病学研究登记库、微生物学数据库、疫苗接种登记库、死因登记库和劳动力市场研究数据库)的全国登记研究。
- 纳入2020年1月1日至3月1日期间居住于丹麦的所有18岁及以上精神分裂症谱系障碍(ICD-10:F20-F29)个体,共85 083例(男44 293例[52·1%],女40 790例[47·9%],中位年龄45·8岁[IQR 31·1-60·2]),其中30 984例有抗精神病药暴露期。
- 抗精神病药暴露以时变方式定义,分为现患使用者和新发使用者,并与非暴露期比较;完整观察期为2020年3月1日至2021年12月31日。
- 结局包括轻度感染结局(SARS-CoV-2 PCR阳性及抗感染药物处方)和重度感染结局(COVID-19及非COVID-19呼吸道感染相关住院和死亡),并针对人口学、社会经济因素和合并症进行调整。
主要发现
- 抗精神病药暴露期较非暴露期,SARS-CoV-2检测阳性风险降低(HR 0·91[95%CI 0·85-0·97]),抗感染药物处方风险无统计学显著差异(HR 1·01[95%CI 0·97-1·06])。
- 抗精神病药暴露期较非暴露期,COVID-19相关住院风险升高(HR 1·28[95%CI 1·07-1·52]),COVID-19相关死亡无统计学显著升高(HR 1·24[95%CI 0·82-1·86])。
- 抗精神病药暴露期较非暴露期,非COVID-19呼吸道感染住院风险升高(HR 1·61[95%CI 1·44-1·79]),死亡风险升高(HR 1·61[95%CI 1·18-2·21])。
- COVID-19住院风险在70岁以上个体中升高;非COVID-19住院风险在40岁以上个体中升高,死亡风险在50-59岁和70-79岁年龄组升高。
- 基于同质性检验,氯氮平暴露与其他抗精神病药相比未观察到任何结局的明显超额风险。
临床怎么用
- 作者认为,对40岁以上开始或正在接受抗精神病药治疗的精神分裂症谱系障碍患者启动感染防控措施如肺炎球菌疫苗接种似乎是合理的。
- 作者不建议避免使用特定抗精神病药,而是建议遵循治疗指南并呼吁对该高危群体提高警惕。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Infection risk and mortality are increased in schizophrenia spectrum disorders, which was corroborated during the COVID-19 pandemic. However, evidence is lacking regarding the additional impact of antipsychotic drugs, and the highly debated safety of clozapine treatment during large-scale infection outbreaks. Therefore, we aimed to investigate risk of COVID-19 and non-COVID respiratory infections during exposure to antipsychotics. METHODS: We used several nationwide Danish registers (National Prescription Registry, National Hospital Registry, Psychiatric Research Register, Microbiology Database, Vaccination Registry, Cause of Death Registry, and Database for Labour market Research) to investigate all individuals aged 18 years or older with a schizophrenia spectrum disorder (ICD-10: F20-F29) living in Denmark between Jan 1 and March 1, 2020. Antipsychotic exposure groups were defined as prevalent-users and incident-users. The full observation period was March 1, 2020 to Dec 31, 2021. Antipsychotic exposure was defined in a time-varying manner and compared with non-exposure. Risk was calculated for mild infection outcomes (positive SARS-CoV-2 PCR and anti-infective drug prescriptions) and severe infection outcomes (hospitalisation and death) related to COVID-19 and non-COVID-19 respiratory infections. Outcomes were adjusted for demographics, socio-economic factors, and comorbidity. FINDINGS: Of 85 083 individuals (44 293 men [52·1%] and 40 790 women [47·9%], median age 45·8 years [IQR 31·1-60·2]) with pre-existing schizophrenia spectrum disorders, 30 984 had antipsychotic exposure periods. Ethnicity data were not available. During antipsychotic exposure compared with non-exposed periods, assessing mild infection outcomes, risk of a positive SARS-CoV-2 test was decreased (hazard ratio 0·91 [95% CI 0·85-0·97]) and risk of redeeming an anti-infective drug was not statistically significantly different (1·01 [0·97-1·06]). For severe infection outcomes, COVID-19-related hospitalisation risk was increased (1·28 [1·07-1·52]) although COVID-19-related death was not statistically significantly increased (1·24 [0·82-1·86]). For non-COVID-19 respiratory infections, risk was increased both for hospitalisation (1·61 [1·44-1·79]) and death (1·61 [1·18-2·21]). Specifically, COVID-19 hospitalisation risk was increased in individuals older than 70 years, and non-COVID-19 hospitalisation risk increased in individuals older than 40 years and death risk in age groups of 50-59 years and 70-79 years. Based on homogeneity testing, no apparent excess risk of any outcome was observed with clozapine exposure compared with other antipsychotics. INTERPRETATION: During antipsychotic exposure compared with unexposed periods, risk of severe infection outcomes increases. It seems reasonable to initiate infection countermeasures, such as pneumococcal vaccination, in people older than 40 years with schizophrenia spectrum disorders, who commence or are treated with antipsychotics. We do not suggest the avoidance of specific antipsychotics but rather adherence to treatment guidelines and a call for increased vigilance regarding this at-risk group. FUNDING: Mental Health Services of the Capital Region of Denmark.
引用
- Nersesjan V, Christensen RHB, Andersen EW, et al. Antipsychotic exposure and infection risk in people with schizophrenia spectrum disorders during the COVID-19 pandemic: a Danish nationwide registry study. Lancet Psychiatry. 2024. PMID: 39241794. doi:10.1016/S2215-0366(24)00223-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。